Biocytogen Enters into Antibody Evaluation Option and License Agreement with Myricx for ADC Development

Biocytogen Pharmaceuticals a global biotech company focusing on the discovery of novel antibody therapeutics today announces an antibody evaluation option and license agreement with Myricx Bio a UK biotech company focusing on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates ADCs.

Related Keywords

London ,City Of ,United Kingdom ,Beijing ,China ,United States ,Shanghai ,San Francisco ,California ,Yuelei Shen ,Robin Carr ,Myricx Bio ,Haimen Jiangsu ,Integrum Renmice ,Biocytogen Pharmaceuticals Beijing Co Ltd ,Myricx Pharma ,Francis Crick Institute ,Imperial College London ,Linkedin ,Project Integrum ,Sofinnova Partners ,Brandon Capital ,Media Contact ,Biocytogen Pharmaceuticals Biotech Company Antibody Therapeutics Myricx Bio Drug Conjugates Adcs Cytotoxic Payloads Renmice Dr Yuelei Shen Nmti Robin Carr Renmab Renlite Rennano ,